Primary Radiotherapy In MEtastatic Lung Cancer

Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Thoracic Oncology Group of Australasia (TOGA), Canadian Pulmonary Radiation Investigators (CAPRI), Irish Cancer Trials (ICTG) & Peter MacCallum Cancer Centre / AURORA

Accrual Target

420

Expected Date of Accrual

31 December 2030

Trial Chairperson

Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC, Australia

Trial Contact

Clinical Trial Registration

Related Post

17 September, 2026

Meet the TROG Quality Assurance team

TROG UPDATES: 17 September 2026 Our Quality Assurance team

17 September, 2026

TROG trial of new lung cancer radiation therapy approach opens

LATEST NEWS: 17 September 2026 The first Australian site